How KPV works
KPV is the C-terminal tripeptide of α-MSH. It enters cells and interferes with NF-κB and interferon-γ signalling, damping pro-inflammatory cytokine output locally — in intestinal epithelium and in skin — without broad immune suppression.
Reported benefits
- Reduced gut and mucosal inflammation
- Calmer inflammatory skin conditions
- Supports epithelial barrier integrity
- Effective topically and systemically
Reported side effects
Effects reported in published trials, case reports or post-market surveillance. Individual response varies; this list is educational and not exhaustive.
- Injection-site or topical irritation
- Mild gastrointestinal upset when taken orally
- Limited controlled human safety data
Regulatory status & sources
Not FDA approved — research use only
No FDA approval. KPV is the C-terminal fragment of α-MSH studied preclinically for gut and skin inflammation.
Safety note
KPV is presented here for research and educational purposes only. It is not offered for human consumption and nothing on this page is medical advice or a dosing protocol. Read the full safety and disclaimer page.